A5005245681- Sperm and Testicular Function
- Testicular diseases and treatments
- Sexual Differentiation and Disorders
- Reproductive Biology and Fertility
- Hormonal and reproductive studies
- Reproductive Health and Technologies
- Legal and Regulatory Analysis
- Sexual function and dysfunction studies
- Healthcare Systems and Public Health
- Genital Health and Disease
- Childhood Cancer Survivors' Quality of Life
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Pelvic floor disorders treatments
- Pharmacology and Obesity Treatment
- Renal and related cancers
- Sarcoma Diagnosis and Treatment
- Male Reproductive Health Studies
- Female Genital Mutilation/Cutting Issues
- Prenatal Screening and Diagnostics
- Sexuality, Behavior, and Technology
- Comparative and International Law Studies
- Muscle metabolism and nutrition
- Ovarian cancer diagnosis and treatment
Erasmus MC Cancer Institute
2019-2025
Erasmus MC
2016-2025
Erasmus University Rotterdam
2014-2023
Urological Society of Australia and New Zealand
2023
Oxfam
2023
Liechtenstein Institute
2023
John Wiley & Sons (United States)
2023
Testicular cancer incidence among adolescents and young adults (AYAs, aged 18-39 years at diagnosis) is increasing worldwide most patients will survive the initial disease. Still, detailed epidemiological information about testicular AYAs scarce. This study aimed to provide a overview of trends in incidence, treatment, long-term relative survival mortality by histological subtype diagnosed Netherlands between 1989 2019.
Abstract Purpose To describe recall of fertility-related consultations and cryopreservation to examine reproductive goals reproduction post-treatment in long-term survivors adolescent young adult (AYA) (age, 18–39 years) cancer. Methods This study included n = 1457 male 2112 female ( M age 43–45 years; 5–22 years from diagnosis) who provided self-report. Clinical data were supplied by the Netherlands Cancer Registry. Results Most (72.7%) recalled 22.6% completed sperm cryopreservation....
Abstract Background The microRNA‐371a‐3p (miR‐371a‐3p) has been reported to be an informative liquid biopsy (serum and plasma) molecular biomarker for both diagnosis follow‐up of patients with a malignant (testicular) germ cell tumor ((T)GCT). It is expressed in all histological cancer elements, the exception mature teratoma. However, normal testis, semen, serum males disrupted testicular integrity without TGCT may contain miR‐371a‐3p levels above threshold, which cellular origin unknown....
Abstract Testicular sperm is increasingly used during in vitro fertilization treatment. has the ability to fertilize oocyte after intracytoplasmic injection (ICSI), but they have not undergone maturation epididymal transport. differs from ejaculated terms of chromatin maturity, incidence DNA damage, and RNA content. It fully understood what biological impact using testicular sperm, on fertilization, preimplantation embryo development, postimplantation development. Our goal was investigate...
Summary The aim of this study was to compare sperm DNA damage between men with a history congenital undescended testis ( UDT ) and acquired . A long‐term follow‐up previous performed. Fifty who had undergone orchiopexy at childhood age, 49 after ‘wait‐and‐see’‐protocol (e.g. awaiting spontaneous descent until puberty perform an in case non‐decent), 22 healthy proven fertile were included. fragmentation index DFI using chromatin structure assay SCSA used express the level damage. Decreased...
Semencryopreservatie is een algemeen geaccepteerde methode om kinderwens in de toekomst mogelijk te maken voor mannen die door gonadotoxische chemo- of radiotherapeutische behandeling onvruchtbaar dreigen worden. In retrospectief onderzoek cohort van 604 met maligne testistumor, toonden wij aan dat bij op zes patiënten semencryopreservatie niet suboptimaal was verband azoöspermie, aspermie cryptozoöspermie. Bij deze kan testiculaire sperma-extractie (TESE) alternatieve...
Behandeling van kanker kan de spermatogenese aantasten, met infertiliteit tot gevolg. Semencryopreservatie voorafgaand aan gonadotoxische behandeling vruchtbaarheid mannelijke kankerpatiënten veiligstellen. Gedurende 20 jaar zijn 1.018 patiënten tussen 12 en 50 oud, Hodgkin-lymfoom (n = 194), non-Hodgkin lymfoom 110), leukemie 126) of testiculaire kiemceltumoren 588) verwezen naar één centrum voor semencryopreservatie. De incidentie deze kankertypen in het adherentiegebied regionale...
Samenvatting In dit artikel worden praktische aspecten van semencryopreservatie, chirurgische zaadcelwinning door middel oncoTESE bij azoöspermie en fertiliteitcounseling zaadbalkankerpatiënten besproken.